Key result
The SAMe-TT2R2 score identifies atrial fibrillation patients likely to do well on a vitamin K antagonist (score 0-1) versus those likely to achieve suboptimal time in therapeutic range (score ≥2).
Why the study?
Does the SAMe-TT2R2 score help guide decision-making between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation?
Does the SAMe-TT2R2 score help guide decision-making between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation?
The SAMe-TT2R2 score is a useful clinical tool to guide the choice between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants by predicting the likelihood of achieving good time in therapeutic range.
Oral anticoagulation therapy is essential in patients with atrial fibrillation and clinicians need guidance on decision-making between the vitamin K antagonists (VKA), e.g. warfarin, or non-vitamin K antagonist oral anticoagulants. Observational studies have shown that patients who receive VKA therapy spend a significant percentage of their time with international normalized ratio values outside of the therapeutic range (time in therapeutic range, TTR <60%.) Recently, a clinical score has been developed with commonly encountered clinical features, the SAMe-TT2R2 score, to help decision-making with regard to whether a patient is likely to do well, or not, with a VKA. Those with a SAMe-TT2R2 score of 0-1 are likely to do well on a VKA, while those with a SAMe-TT2R2 score ≥ 2 are on probability going to achieve suboptimal TTR. In this article, we provide an overview of the main published retrospective and prospective studies that have validated the SAMe-TT2R2 score and its value for decision-making in daily clinical practice.
No takes yet. Share an insight, caveat, or question.
Esteve‐Pastor et al. (2015) conducted a review in atrial fibrillation. SAMe-TT2R2 score was evaluated. The SAMe-TT2R2 score identifies atrial fibrillation patients likely to do well on a vitamin K antagonist (score 0-1) versus those likely to achieve suboptimal time in therapeutic range (score ≥2).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: